Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumour × Fluorouracil × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 407 Rectal Neoplasms 231 Colonic Neoplasms 189 Stomach Neoplasms 162 Pancreatic Neoplasms 159 Esophageal Neoplasms 118 Breast Neoplasms 101 Neoplasm Metastasis 99 Head and Neck Neoplasms 78 Neoplasms 75 Squamous Cell Carcinoma of Head and Neck 73 Adenocarcinoma Of Esophagus 58 Esophageal Squamous Cell Carcinoma 48 Carcinoma, Hepatocellular 47 Adenocarcinoma 36 Nasopharyngeal Carcinoma 31 Cholangiocarcinoma 29 Gastrointestinal Neoplasms 22 Biliary Tract Neoplasms 22 Anus Neoplasms 22 Keratosis, Actinic 21 Carcinoma, Non-Small-Cell Lung 21 Gallbladder Neoplasms 20 Carcinoma, Squamous Cell 19 Urinary Bladder Neoplasms 18 Liver Neoplasms 18 Bile Duct Neoplasms 18 Parkinson Disease 4, Autosomal Dominant Lewy Body 16 Nasopharyngeal Neoplasms 14 Unspecified Adult Solid Tumor, Protocol Specific 12

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡